QCG
INBX icon

Quadrant Capital Group’s Inhibrx INBX Stock Holding History

Quadrant Capital Group’s Portfolio INBX Stock Details INBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.7K Buy
+55
New +$4.08K ﹤0.01% 2414
2025
Q1 		– Sell
-146
Closed -$2.25K – 2799
2024
Q4 		$2.25K Sell
146
-25
-15% -$381 ﹤0.01% 2480
2024
Q3 		$2.68K Hold
171
– – ﹤0.01% 2446
2024
Q2 		$2.42K Buy
+171
New +$2.67K ﹤0.01% 2443

Other funds holding INBX

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
S
Sanofi Paris, France $336M AUM 126.85% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Quadrant Capital Group's INBX Position: Q1 2026 in Review

Quadrant Capital Group opened a new position in Inhibrx (INBX) in Q1 2026: 55 shares worth $3.7K. The stake represents ﹤0.01% of the portfolio and ranks #2414 among its holdings. This is a return to the name: Quadrant Capital Group previously reported a position in INBX as recently as Q4 2024.

Quadrant Capital Group first reported a position in INBX in Q2 2024 and has held it in 4 quarters since. 135 funds tracked by Wall St. Rank hold INBX as of Q1 2026.

  • Quadrant Capital Group held 55 shares of Inhibrx worth $3.7K as of Q1 2026.
  • Inhibrx was a new Quadrant Capital Group position in Q1 2026.
  • Inhibrx made up ﹤0.01% of Quadrant Capital Group's portfolio in Q1 2026, its #2414 holding.
  • Quadrant Capital Group first reported a position in Inhibrx in Q2 2024 and has held it in 4 quarters since.
  • 135 funds tracked by Wall St. Rank held Inhibrx as of Q1 2026.

Based on Quadrant Capital Group's 13F filing for Q1 2026, filed 11 May 2026.